DLBCL

Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.

Two immune systems conditions, hypogammaglobulinemia and hypocomplementemia, may be predictive of adverse outcomes in patients with diffuse large B-cell lymphoma, according to a published study.

Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.

The first CD19/22-directed dual targeting CAR T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the remaining unmet needs that exist in the treatment landscape of diffuse large B-cell lymphoma.

Despite concerns about treatment-related immunosuppression, a report out of Spain suggests SARS-CoV-2 precautions can offset risk for patients with diffuse large B-cell lymphoma.

A review was conducted to understand how precision medicine strategies can be successfully implemented in diffuse large B-cell lymphoma

John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, discusses the role of tafasitamab and lenalidomide following the approval of this agent as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

A Biologics License Application was submitted to the FDA for loncastuximab tesirine, an antibody-drug conjugate, as treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.